Financial Performance - The company's operating revenue for 2023 was approximately RMB 4.43 billion, representing an increase of 11.62% compared to RMB 3.97 billion in 2022[21]. - The net profit attributable to shareholders for 2023 was approximately RMB 59.53 million, a significant increase of 41.69% from RMB 42.02 million in 2022[21]. - The net profit after deducting non-recurring gains and losses was approximately RMB 54.03 million, up 37.40% from RMB 39.32 million in 2022[21]. - The total assets at the end of 2023 were approximately RMB 1.69 billion, reflecting a growth of 6.00% from RMB 1.59 billion at the end of 2022[21]. - The basic earnings per share for 2023 were RMB 0.62, an increase of 40.91% compared to RMB 0.44 in 2022[21]. - The cash flow from operating activities showed a net outflow of approximately RMB 115.47 million, a decline of 175.64% compared to a net inflow of RMB 152.67 million in 2022[21]. - The weighted average return on equity for 2023 was 7.16%, an increase of 1.87% from 5.29% in 2022[21]. - The company reported quarterly revenues of RMB 1.22 billion in Q4 2023, with a net profit of RMB 9.37 million for the same quarter[23]. - The company's revenue increased from CNY 3.969 billion in 2022 to CNY 4.430 billion in 2023, representing a year-on-year growth of 11.62%[80]. - The net profit attributable to shareholders reached CNY 59.53 million in 2023, a year-on-year increase of 41.69%[80]. - The company's terminal pure sales amounted to CNY 2.504 billion in 2023, reflecting a growth of 5.56% compared to the previous year[80]. Market Trends and Industry Insights - The total sales volume of China's pharmaceutical circulation market reached CNY 2,751.6 billion in 2022, with a year-on-year growth of 6.0%[31]. - The retail pharmaceutical market sales amounted to CNY 599.0 billion, reflecting a year-on-year increase of 10.7%[31]. - The wholesale pharmaceutical market sales were CNY 2,152.6 billion, with a year-on-year growth of 5.4%[31]. - The market share of public hospitals has decreased to 61.8%, while retail pharmacies have increased their market share to 29%[33]. - By 2029, the external market is expected to reach CNY 1.6 trillion, potentially surpassing the internal market[34]. - The implementation of the Marketing Authorization Holder (MAH) system has led to over 2,000 companies obtaining B-class drug production licenses, enhancing industry competition[35]. - New regulations for online drug sales are expected to promote the healthy development of the pharmaceutical e-commerce sector[36]. - The "Seven Unifications" policy is set to enhance the regional collaborative advantages of large-scale enterprises starting January 1, 2024[37]. - The online sales proportion in the pharmaceutical retail market reached 28.9% in 2022, up from 8.1% in 2017, indicating a significant shift towards digital channels[42]. - The outpatient market for prescription drugs in China is currently below 30%, indicating significant growth potential compared to over 70% in countries like the US and Japan[147]. Business Strategy and Operations - The company's main business includes a comprehensive pharmaceutical distribution service, focusing on the outpatient market, which aligns with the trend of shifting from hospital to outpatient markets[44]. - The company operates approximately 23,000 pharmaceutical products across various categories, including Western medicine, traditional Chinese medicine, and medical devices, to meet outpatient market demands[49]. - The company has established a SBBC (Suppliers to key Business partners to small Business partners to Customers) ecosystem, enhancing supply chain efficiency and reducing distribution costs[46]. - The company has 14 wholly-owned subsidiaries, 14 holding companies, and 15 joint-stock companies, indicating a robust corporate structure for expansion[48]. - The company aims to become a leader in the digital health ecosystem by leveraging innovative technologies and enhancing service capabilities[44]. - The implementation of outpatient management in retail pharmacies is expected to boost the outpatient market's growth potential significantly[40]. - The company has been recognized as a national-level e-commerce demonstration enterprise, reflecting its industry standing and commitment to innovation[44]. - The integration of digital technologies in the pharmaceutical supply chain is essential for enhancing service efficiency and establishing a new business model in the industry[39]. - The company has established a distribution system with over 3,500 lower-level distributors, enhancing its market reach[50]. - The company has built a logistics system with independent operations through its wholly-owned subsidiary, Yao Yida Logistics, to meet the increasing demand for timely delivery[58]. E-commerce and Digital Transformation - The company has successfully established an online retail team and store matrix, with significant growth in online retail business from its invested companies[61]. - The company has achieved 78,800 effective customers through its e-commerce platform by the end of 2023, representing a growth rate of 7.87% compared to 2022[65]. - The average weekly active users (stores) reached 15,500 in 2023, with a growth rate of 5.80% from the end of 2022[65]. - E-commerce business revenue for 2023 was reported at 1.707 billion yuan, with a slight decrease of 2.01% from 2022[72]. - The average transaction amount per order was 1,251.48 yuan in 2023, showing an increase of 5.83% compared to the previous year[65]. - The company has signed contracts with 52 suppliers for advertising services, generating a total of 1.2344 million yuan in revenue[66]. - The company has established a comprehensive pharmaceutical service ecosystem in the outpatient market, enhancing supply chain advantages and expanding product resources[74]. - The company has invested in smart warehousing and logistics, improving operational efficiency and reducing costs through modernized systems[75]. - The company has focused on integrating traditional pharmaceutical distribution with internet and big data technologies, significantly enhancing transaction efficiency[72]. - The company has developed a digital health ecosystem, integrating AI, big data, and internet solutions to enhance operational efficiency and support business strategies[60]. Research and Development - The company achieved a research and development investment of ¥33,218,791.22 in 2023, representing an increase from ¥17,707,719.44 in 2022[108]. - The R&D investment accounted for 0.75% of the company's operating revenue in 2023, up from 0.45% in 2021[108]. - The number of R&D personnel increased to 119 in 2023, a growth of 1.71% compared to 117 in 2022[108]. - The company has increased its focus on drug research and development, leveraging partnerships with large pharmaceutical research institutions[108]. - The proportion of capitalized R&D expenditures reached 42.31% of total R&D investment in 2023[108]. Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operations from its controlling shareholder[170]. - The board of directors consists of 8 members, including 3 independent directors, meeting legal requirements and ensuring effective governance[171]. - The company has implemented a fair and effective performance evaluation and incentive mechanism for senior management, combining base salary with annual performance assessments[175]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations, with no violations reported regarding fund occupation or guarantees[177]. - The annual shareholders meeting held on May 11, 2023, had an investor participation rate of 63.72%[178]. - The first extraordinary shareholders meeting on September 13, 2023, recorded a participation rate of 56.84%[179]. - The company is currently led by a board of directors with a mix of experienced professionals, including a chairperson and several independent directors[181]. - The company has a total of 12 directors and supervisors, with varying levels of remuneration[196]. - The company has established a comprehensive remuneration policy based on operational goals and performance assessments[195]. Risks and Challenges - The company highlighted risks including intensified market competition, changes in market demand, and potential failures in new business expansions[3]. - The company is facing significant risks of failure or substantial initial losses in expanding new businesses, particularly in retail and C-end operations, due to pressures on talent, management capabilities, and long-term mechanisms[163]. - There are ongoing lawsuits related to contract disputes, with uncertain impacts on future profits, prompting the company to form a dedicated team to manage these legal issues[164]. - The company faces risks from intensified market competition and changing market demands, necessitating a focus on enhancing its strengths and expanding coverage in the out-of-hospital market[158]. - The implementation of the MAH system presents new opportunities for transformation in the pharmaceutical distribution sector, while also increasing regulatory pressures[160].

四川合纵药易购医药股份有限公司 信会师报字[2024]第ZD10066号 四川合纵药易购医药股份有限公司全体股东： 2023 年度募集资金存放与使用情况 专项报告的鉴证报告 2023 年度 关于四川合纵药易购医药股份有限公司 2023年度募集资金存放与使用情况 专项报告的鉴证报告 我们接受委托，对后附的四川合纵药易购医药股份有限公司（以 下简称"药易购"） 2023年度募集资金存放与使用情况专项报告（以 下简称"募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 （2022年修订）》（证监会公告〔2022〕15号）、《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》以及《深 圳证券交易所创业板上市公司自律监管指南第2号——公告格式》的 相关规定编制，如实反映药易购2023年度募集资金存放与使用情况获 取合理保证。在执行鉴证工作过程中，我们实施了包括询问、检查会 计记录等我们认为必要的程序。我们相信，我们的鉴证工作为发表鉴 证结论提供了合理的基础。 药易购董事会的责任是按照中国证券监督管理委员会《上市公司 监管指引第2号——上市公司募集资金管理和使用的监管要求（2022 年修 ...

四川合纵药易购医药股份有限公司 2023 年度独立董事述职报告 一、个人基本情况 （一）工作履历、专业背景以及兼职情况 本人罗响，1970 年 12 月出生，工商管理博士，拥有超过 20 年在联合国担 任高级官员的卓越领导力、丰富的国际工作经验与本地化执行能力。现任联合国 工业发展组织全球创新网络 ESG&碳中和投资指导委员会（SCECNI）主席，系 在联合国可持续发展议程框架下为支持实现可持续发展目标（SDG）及全球碳中 和雄心计划而专注于为实现路径提供战略顾问、特别项目筹款、碳中和投资、减 排科技及作为联合国及其他国际机构的执行合作伙伴、资金筹集伙伴、顾问及技 术支持伙伴；现任山东矿机集团股份有限公司独立董事。罗响先生亦曾兼任美国 麻省理工学院（MIT）创业投资指导，世界自然基金会（WWF）中国区气候创 行计划核心专家，社会影响力投资与采购基金会（SIIP） 联席主席，《经济日 报集团》评为"2020 中国智慧经济十大领军人物"。自 2022 年 7 月 18 日起任 公司独立董事。 （二）独立性情况说明 本人不在公司担任除独立董事外的其他职务，不存在任何妨碍本人进行独立 客观判断的关系，不存在《上市公司 ...

四川合纵药易购医药股份有限公司董事会 经核查独立董事罗响、刘磊、邓博夫的任职经历以及签署的相关自查文件， 上述人员在 2023 年度任职期间均能够胜任独立董事的职责要求，未在公司担任 除独立董事以外的任何职务,也未在公司主要股东公司担任任何职务，与公司以 及主要股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系，不 存在违反独立董事独立性要求的情形，因此，公司独立董事符合《上市公司独立 董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号一一创业板上市 公司规范运作》中对独立董事独立性的相关要求。 四川合纵药易购医药股份有限公司 董事会 2024 年 4 月 8 日 关于独立董事独立性自查情况的专项意见 根据证监会《上市公司独立董事管理办法》《深圳证券交易所创业板股票上 市规则》、《深圳证券交易所上市公司自律监管指引第 2 号一创业板上市公司规 范运作》等要求，四川合纵药易购医药股份有限公司（以下简称"公司"）董事 会，就公司在任独立董事罗响、刘磊、邓博夫的独立性情况进行评估并出具如下 专项意见： ...

证券代码：300937 证券简称：药易购 公告编号：2024-018 四川合纵药易购医药股份有限公司 关于为子公司申请授信提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2024 年 4 月 8 日 召开了第三届董事会第二十一次会议，审议通过了《关于为子公司申请授信提供 担保的议案》。为满足其日常经营发展的需要，同意公司为全资子公司四川康正 康乐康大药房连锁有限公司（以下简称"康乐康连锁药房"）向银行申请不超过 人民币 5,000 万元的综合授信提供连带责任保证担保，为全资子公司四川合纵药 达天下医药有限公司（以下简称"药达天下"）向银行申请不超过人民币 5,000 万元的综合授信提供连带责任保证担保，为全资子公司河南齐力康医药有限公司 （以下简称"河南齐力康"）向银行申请不超过人民币 10,000 万元的综合授信提 供连带责任保证担保。担保期限自担保协议生效之日起一年。 本次担保不属于关联担保，根据《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引 ...

四川合纵药易购医药股份有限公司 审计报告及财务报表 二○二三年度 四川合纵药易购医药股份有限公司 审计报告及财务报表 （2023 年 01 月 01 日至 2023 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-129 | 审计报告 信会师报字[2024]第 ZD10064 号 四川合纵药易购医药股份有限公司全体股东： 一、 审计意见 我们审计了四川合纵药易购医药股份有限公司（以下简称"药易 购"）财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表， 2023 年度的合并及母公司利润表、合并及母公司现金流量表、合并 及母公司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照 ...

证券代码：300937 证券简称：药易购 公告编号：2024-022 四川合纵药易购医药股份有限公司 关于 2023 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 如在利润分配预案披露至实施期间，公司总股本发生变动的，公司拟以维持 每股分配比例不变的原则，相应调整分配总数。 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2024 年 4 月 8 日召开了第三届董事会第二十一次会议、第三届监事会第十四次会议，分别审议 通过了《关于公司 2023 年度利润分配预案的议案》，该议案尚需提交公司 2023 年度股东大会审议。现将具体情况公告如下： 一、利润分配预案 1、利润分配预案的具体情况 根据立信会计师事务所（特殊普通合伙）出具的标准无保留审计报告，母公 司 2023 年度实现净利润 61,644,767.32 元。根据《公司法》和《公司章程》规定， 以 2023 年度实现的母公司净利润 61,644,767.32 元为基数，提取 10%的法定盈余 公积金计人民币 6,164,476.73 元，截至 2023 年 12 月 31 ...

证券代码：300937 证券简称：药易购 公告编号：2024-016 四川合纵药易购医药股份有限公司 关于 2024 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2024 年 4 月 8 日召开了第三届董事会第二十一次会议、第三届监事会第十四次会议，分别审议 通过了《关于 2024 年度日常关联交易预计的议案》，公司根据实际经营情况预 计未来可能与四川神鸟世纪科技有限公司（以下简称"神鸟世纪"）、四川玉鑫 中医世家医药连锁有限公司（以下简称"玉鑫中医世家"）、广东世纪美康药房 有限公司（以下简称"世纪美康"）、广东泓然堂医药有限公司（以下简称"广 东泓然堂"）、四川合纵中药饮片有限公司（以下简称"中药饮片厂"）、广东 伟哥药品有限公司（以下简称"广东伟哥"）、成都市闪送易购智能设备有限公 司（以下简称"闪送易购智能设备"）、湖州市见素易购医药科技有限公司（以 下简称"见素易购医药科技"）发生日常关联交易，金额最高不超过人民币 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"）于 2024 年 4 月 8 日召开了第三届董事会第二十一次会议、第三届监事会第十四次会议，分别审议 通过了《关于 2024 年向银行申请授信额度并接受关联方担保的议案》，现将具 体内容公告如下： 一、关联交易概述 为满足业务发展需要，公司及全资子公司拟在 2024 年度根据实际经营情况 和需求向银行申请累计不超过人民币 6 亿元的综合授信额度，公司控股股东、实 际控制人、董事长李燕飞女士及/或公司董事周跃武先生无偿为公司上述授信提 供连带责任保证担保。上述综合授信事项有效期不超过一年，自股东大会审议通 过之日起计算，在以上额度范围内可循环使用，具体授信金额、授信方式等最终 以公司及全资子公司与银行实际签订的正式协议或合同为准。董事会授权公司董 事长李燕飞女士在上述额度内签署授信相关合同。 李燕飞女士为公司董事长、公司控股股东、实际控制人，周跃武先生为公司 董事及李燕飞女士的一致行动人，根据《深圳证券交易所创业板股票上市规则》 等有关规定，李燕飞女士、周跃武先生为 ...

证券代码：300937 证券简称：药易购 公告编号：2024-021 四川合纵药易购医药股份有限公司 2023年度募集资金存放与使用情况专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》的相关规定，四川合纵药易购医药股份有限公司（以下简称"公司"、"本 公司"）就 2023 年度募集资金存放与使用情况作如下专项报告： 募集资金基本情况 经中国证券监督管理委员会《关于同意四川合纵药易购医药股份有限公司首 次公开发行股票注册的批复》（证监许可[2020]3568 号）核准，并经深圳证券交 易所同意，公司由主承销商申万宏源证券承销保荐有限责任公司向社会公开发行 人民币普通股（A 股）23,916,671.00 股，发行价格为每股 12.25 元，募集资金总 额 292,979,219.75 元，扣除发行费用 43,505,924.32 元（不含税），实际募集资 金净额为人民币 249,473,295.43 元 ...